HR 1958: Deporting Fraudsters Act of 2026

The "Deporting Fraudsters Act of 2026" (H.R. 1958) amends the Immigration and Nationality Act to make aliens convicted of defrauding the U.S. government or unlawfully receiving public benefits inadmissible and deportable. This bill was reported by the House Committee on the Judiciary and ordered to be printed.

H.R. 1958 Deporting Fraudsters Act Hearing Announcement

The US House Committee on the Judiciary announced a hearing for H.R. 1958, the Deporting Fraudsters Act of 2026. The hearing is scheduled for Tuesday, March 3, 2026, and will discuss the proposed legislation.

H.R. 4638 BOWOW Act of 2025 - Immigration inadmissibility for harming law enforcement animals

H.R. 4638, the BOWOW Act of 2025, was introduced in the US House of Representatives. This bill proposes to amend the Immigration and Nationality Act to make aliens inadmissible and deportable if convicted of harming animals used in law enforcement.

H.R. 4638 - BOWOW Act of 2025 Hearing Announcement

The US House Committee on the Judiciary announced a hearing for H.R. 4638, the BOWOW Act of 2025, scheduled for March 3, 2026. The bill text and committee report are available for review.

NCCI Loss Costs Accepted with 3.8% Decrease for Workers' Compensation

The Texas Department of Insurance (TDI) has accepted the NCCI advisory loss cost filing, resulting in an average 3.8% decrease for workers' compensation insurance, effective July 1, 2026. Insurance companies writing workers' compensation in Texas must submit rate filings by June 1, 2026, using the new loss costs.

EMA CHMP Recommends 12 Medicines for Approval

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended 12 new medicines for approval and six for extension of therapeutic indications. This includes novel treatments for influenza, COVID-19, paediatric brain tumours, Parkinson's disease, and several biosimilar medicines.

EMA Recommends Ojemda for Paediatric Low-Grade Glioma

The European Medicines Agency (EMA) has recommended a conditional marketing authorisation for Ojemda (tovorafenib) to treat paediatric low-grade glioma in patients aged 6 months and older with specific BRAF gene alterations. This recommendation addresses an unmet medical need for a targeted therapy in this patient population.

California Officials Seize Illegal Cannabis Plants Worth $57 Million

California state officials, led by Governor Gavin Newsom, announced the seizure of over 58,000 illegal cannabis plants and approximately three tons of processed cannabis in November. The operation, conducted by the Department of Cannabis Control, targeted the illicit market and resulted in the eradication of plants and product valued at an estimated $56.5 million.

Cannabis Business Dispute and Fraud Avoidance Guidance

The California Department of Cannabis Control (DCC) has issued guidance on avoiding business disputes and fraud within the cannabis industry. The document outlines proactive measures for vetting partners, understanding contracts, and maintaining records to prevent common pitfalls.

DCC Awards $30 Million in Cannabis Research Grants

The California Department of Cannabis Control (DCC) awarded nearly $30 million in research grants to nine academic institutions for 22 projects. This funding, derived from cannabis tax revenues, supports research on economic dynamics, public health, and environmental impacts related to cannabis.